Molecular Mechanisms of Liver Fibrosis
Molecular Mechanisms of Liver Fibrosis
批准号:
10152468
负责人:
VIJAY H. SHAH
金额:
$35.78万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-05-10 至 2022-04-30
关键词:
AlcoholsAttenuatedAutophagocytosisBindingBinding ProteinsBiologicalCell NucleusCell membraneCellular biologyCirrhosisClinicalDataDepositionDevelopmentEZH2 geneEndosomesEpigenetic ProcessEtiologyFibrosisGene ActivationGene ExpressionGene Expression RegulationGenesGeneticGenetic TranscriptionGoalsGrowth FactorHepatic Stellate CellHistonesHumanIGFBP3 geneImageInsulinInvestigationLeadLiver FibrosisMagnetic Resonance ElastographyMediatingModelingModificationMolecularMorbidity - disease rateMusPeptidesPharmacologyPhenotypePlatelet-Derived Growth Factor alpha ReceptorPreventionProcessProductionProteinsReceptor Protein-Tyrosine KinasesReceptor SignalingRoleSignal TransductionSignaling ProteinTechnologyTestingTransferaseVesicleWorkcell motilityepigenetic regulationfibrogenesishistone methylationin vivoinnovationinnovative technologiesknock-downliver injurymigrationmortalitynovelprotein transportpublic health relevancerecruittherapeutic targettraffickingtranscriptome sequencing
中文摘要
项目总结/文摘:
英文摘要
PROJECT SUMMARY/ABSTRACT:
Liver injury from alcohol and other etiologies can culminate in cirrhosis with significant associated morbidity
and mortality. Hepatic stellate cell (HSC) activation encompasses a phenotype that includes enhanced
migration, proliferation, and matrix deposition. Migration is critical for coordinately situating HSC for matrix
deposition and development of cirrhosis. Our Long-Term Objectives are to understand the molecular
underpinnings of HSC biology that lead to cirrhosis with the goal of identifying therapeutic targets. Recently,
we identified a critical role of synectin in the process of HSC migration and fibrosis. Synectin is a cytosolic
protein that mediates signal transduction, vesicle trafficking, and ultimately gene expression. Synectin is
chosen for this proposal as a significant protein warranting detailed investigation because, as we demonstrate,
it is upregulated in human cirrhosis and is required for murine fibrogenesis. Mechanistically, we implicate
synectin in HSC migration through both short term receptor signaling as well as longer term epigenetic
regulation of gene expression networks. Our preliminary data show that depletion of HSC synectin reduces
migration signaling downstream of the receptor tyrosine kinase, platelet derived growth factor receptor alpha
(PDGFRα); attenuates transcription of a set of HSC activation genes including one that encodes the
multifunctional signaling protein, IGFBP3 (insulin growth factor binding protein-3); and abrogates murine
fibrosis in vivo. These important observations have led us to propose the central hypothesis that synectin
increases HSC migration and fibrosis by promoting PDGFRα signaling and by regulating a network of genes
that include IGFBP3. This hypothesis leads to the following Specific Aims: 1) Synectin promotes HSC
migration by regulating PDGFRα targeting and signal activation. Aim 1a will determine how synectin recruits
and binds specific vesicle trafficking proteins that maintain PDGFRα protein levels, target the protein to
endosomes and activate migration signaling. Aim 1b will uncover how disruption of synectin function leads to
autophagic degradation of PDGFRα and attenuated HSC migration. 2) Synectin epigenetically controls
IGFBP3 gene expression to promote HSC migration. Aim 2a will identify how synectin regulates a specific
histone methyl transferase, EZH2 and how this governs IGFBP3 gene expression through histone methylation.
Aim 2b will determine how IGFBP3 production stimulates HSC migration. 3) Synectin regulates fibrosis in vivo.
Aim 3a will use a novel fibrosis regression model in mice with HSC selective modifications to synectin and
PDGFRα to further ascertain the proposed role of these proteins in vivo. Aim 3b will use a synectin
neutralizing peptide that selectively targets HSC in coordination with magnetic resonance elastography (MRE)
imaging, and mice with genetic deletion of IGFBP3 to elucidate how synectin promotes fibrosis in vivo. In total,
this proposal will utilize conceptually and technically innovative approaches and concepts to test a novel
hypothesis pertaining to synectin as a “master regulator” of HSC signals that lead to migration and fibrosis.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Molecular Mechanisms of Liver Fibrosis
-
批准号:10407227
-
项目类别:
-
资助金额:$35.78万
-
财政年份:2022
-
负责人:VIJAY H. SHAH
-
依托单位:
Molecular Mechanisms of Liver Fibrosis
-
批准号:10612941
-
项目类别:
-
资助金额:$35.78万
-
财政年份:2022
-
负责人:VIJAY H. SHAH
-
依托单位:
Liver Cirrhosis Network: Clinical Research Center - Mayo Clinic
-
批准号:10487453
-
项目类别:
-
资助金额:$29.71万
-
财政年份:2021
-
负责人:VIJAY H. SHAH
-
依托单位:
Liver Cirrhosis Network: Clinical Research Center - Mayo Clinic
-
批准号:10310667
-
项目类别:
-
资助金额:$36.61万
-
财政年份:2021
-
负责人:VIJAY H. SHAH
-
依托单位:
Liver Cirrhosis Network: Clinical Research Center - Mayo Clinic
-
批准号:10700154
-
项目类别:
-
资助金额:$21.04万
-
财政年份:2021
-
负责人:VIJAY H. SHAH
-
依托单位:
Assessment of Alcoholic Hepatitis with Multiparametric Magnetic Resonance Elastography
-
批准号:10459414
-
项目类别:
-
资助金额:$38.17万
-
财政年份:2018
-
负责人:VIJAY H. SHAH
-
依托单位:
Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic Hepatitis
-
批准号:10202402
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2018
-
负责人:VIJAY H. SHAH
-
依托单位:
Assessment of Alcoholic Hepatitis with Multiparametric Magnetic Resonance Elastography
-
批准号:10205237
-
项目类别:
-
资助金额:$38.17万
-
财政年份:2018
-
负责人:VIJAY H. SHAH
-
依托单位:
Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic Hepatitis
-
批准号:9791141
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2018
-
负责人:VIJAY H. SHAH
-
依托单位:
Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic Hepatitis
-
批准号:10449219
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2018
-
负责人:VIJAY H. SHAH
-
依托单位:
Assessment of Alcoholic Hepatitis with Multiparametric Magnetic Resonance Elastography
-
批准号:9791139
-
项目类别:
-
资助金额:$21.74万
-
财政年份:2018
-
负责人:VIJAY H. SHAH
-
依托单位:
Targeting matrix stiffness in lung and liver fibrosis
-
批准号:9165025
-
项目类别:
-
资助金额:$54.06万
-
财政年份:2016
-
负责人:VIJAY H. SHAH
-
依托单位:
Targeting matrix stiffness in lung and liver fibrosis
-
批准号:9332421
-
项目类别:
-
资助金额:$53.9万
-
财政年份:2016
-
负责人:VIJAY H. SHAH
-
依托单位:
TREAT-Mayo
-
批准号:8706608
-
项目类别:
-
资助金额:$3.5万
-
财政年份:2013
-
负责人:VIJAY H. SHAH
-
依托单位:
TREAT-Mayo
-
批准号:8693889
-
项目类别:
-
资助金额:$58.93万
-
财政年份:2012
-
负责人:VIJAY H. SHAH
-
依托单位:
TREAT-Mayo
-
批准号:9524876
-
项目类别:
-
资助金额:$62.5万
-
财政年份:2012
-
负责人:VIJAY H. SHAH
-
依托单位:
Molecular Mechanisms of Liver Fibrosis
-
批准号:9056498
-
项目类别:
-
资助金额:$35.78万
-
财政年份:2012
-
负责人:VIJAY H. SHAH
-
依托单位:
Molecular Mechanisms of Liver Fibrosis
-
批准号:8466909
-
项目类别:
-
资助金额:$33.27万
-
财政年份:2012
-
负责人:VIJAY H. SHAH
-
依托单位:
TREAT-Mayo
-
批准号:8546293
-
项目类别:
-
资助金额:$52.2万
-
财政年份:2012
-
负责人:VIJAY H. SHAH
-
依托单位:
Molecular Mechanisms of Liver Fibrosis
-
批准号:8841284
-
项目类别:
-
资助金额:$34.7万
-
财政年份:2012
-
负责人:VIJAY H. SHAH
-
依托单位:
海外基金